drugset / Trial / NCT05410223

Efficacy and Safety Study of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection

NCT05410223

RandomizedParallel-groupDouble-blindTreatment

Summary

Helicobacter pylori is an important pathogenic factor for gastrointestinal diseases such as gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer.However, with the increasing use of antibiotics, antibiotic resistance of Helicobacter pylori continues to rise. In this study, we used egg yolk antibody combined with bismuth quadruple therapy to treat patients with Helicobacter pylori infection, and observed the eradication rate of Helicobacter pylori, the relief of clinical symptoms and the incidence of adverse reactions.

Timeline

Start
2021-04-06
Primary completion
2022-12-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bismuth Potassium Citrate Unknown
Subject Yolk antibody Protein / enzyme biologic
Background Amoxicillin Other / unclassified
Background Clarithromycin Small molecule
Background Doxycycline Small molecule
Background Furazolidone Small molecule
Background Ilaprazole Small molecule